GENE ONLINE|News &
Opinion
Blog

2022-07-11| ChinaFunding

Zhiyi Biotech Finishes Series B Funding With $45 Million For Live Biotherapeutics

by Joy Lin
Share To

Guangzhou, China-based Zhiyi Biotech has raised $15 million in its B++ funding round, bringing the total amount of funds raised across B, B+, and B++ funding to $45 million. The latest round was joined by a syndicate of Chinese investors, including Qingkong SinoKing Capital, SDIC Venture Capital, and KIP. 

Zhiyi works to isolate and identify new functional strains of microorganisms and turn them into live biotherapeutic products, or LBPs. Its lead product, SK08, is undergoing a Phase 2 study in irritable bowel syndrome (IBS-D) that is expected to be completed this year. The company has also begun another Phase 1b/2 trial of SK08 combined with a PD-1 inhibitor for advanced solid tumors. Other pipeline products are undergoing IND filing to both the US FDA and China’s NMPA.  

Related article: Brii Biosciences Begins Marketing COVID-19 Antibody Cocktail Therapy in China

 

LBPs as Potential Cancer Treatments 

 

The active substance of SK08 is from a bacterial strain of Bacteroides fragilis, a common gut bacteria. Notably in 2019, SK08 became the first LBP in oncology to reach the clinic in China. Preclinical studies on SK08 suggest that the LBP may promote T-cell migration and proliferation, dendritic cell maturation and inflammation such as cytokine secretion in the tumor microenvironment. 

While LBPs are slowly gaining interest as a cancer treatment, drug developers must pay attention to the quality, safety and efficacy of their candidate. A concern is how the strain reaches the tumor, and the possibility of unwanted sepsis, infection, or inflammation. The strain must also be designed to be unable to transfer antibiotic resistance to other microbes. 

To ensure the purity of their LBPs, Zhiyi has established a platform system for strain selection, drug ability study, CMC study, and owns two commercial-scale plants for production.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Zenas Picks Up $118 Million To Advance Phase 3 For Autoimmune Candidate
2022-11-10
Lepu, HanX Scores China Approval For PD-1 Inhibitor
2022-07-27
Delfi Diagnostics Amasses $225 Million for Early Cancer Screening
2022-07-19
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!